Pliant Therapeutics Inc (STU:9PT)
€ 13.3 0.4 (3.05%) Market Cap: 833.15 Mil Enterprise Value: 487.01 Mil PE Ratio: 0 PB Ratio: 2.23 GF Score: 35/100

Pliant Therapeutics Inc at Canaccord Genuity Growth Conference Transcript

Aug 10, 2023 / 02:00PM GMT
Release Date Price: €16.9 (+6.29%)
Unidentified Participant

(inaudible) With us today, I have the pleasure of having the senior management of Pliant Therapeutics. With us we have Bernard Coulie, who is the President and Chief Executive Officer; Ãric Lefebvre, who's the Chief Medical Officer; and Keith Cummings, Chief Financial Officer. Thank you all for joining us today.

Questions & Answers

Unidentified Participant

So to start off, I wanted to maybe you could give us some background for the audience. Could you just give us a brief introduction to Pliant, and just maybe just kind of the overarching theme on ongoing R&D pipeline.

Bernard Coulie
Pliant Therapeutics, Inc. - President & CEO

Absolutely. And thanks, Ed, thanks for having us. So I kind of would kick it off with just a brief description of Pliant, and then Keith will kind of go into the details as it relates to our financials.

So Pliant started about seven years ago located in South San Francisco. We are focused on developing novel treatments for fibrotic diseases. The target class

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot